| [1] |
Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer[J].Lancet Oncol,2001,2(3):133-140.
|
| [2] |
Jemal A, Siegel R, Ward E, et al. Cancer statistics,2009[J]. CA Cancer J Clin,2009,59(4):225-249.
|
| [3] |
Sorlie T,Tibshirani R,Parker J,et al.Repeated observation of breast tumor subtypes in independent gene expression data sets[J].PNAS,2003,100( 14):8418-8423.
|
| [4] |
Hu Z, Fan C, Oh DS, et al.The molecular portraits of breast tumors are conserved across microarray platforms[J]. BMC Genomics,2006,7(7):96.
|
| [5] |
Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer[J]. Oncogene,2007,26(14):2126-2132.
|
| [6] |
Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma[J].Mod Pathol,2006,19(2):264-271.
|
| [7] |
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study[J].JAMA,2006,295(21):2492-2502.
|
| [8] |
韩晓蓉,郜红艺,王颀,等.三阴性乳腺癌的临床病理特点(附35 例报告) [J/CD].中华乳腺病杂志:电子版,2009,3(1):16-21.
|
| [9] |
Bauer K, Brown M, Cress R, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor(PR)-negative, and HER-2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer registry[J]. Cancer,2007,109(9):1721-1728.
|
| [10] |
Morris G, Naidu S, Topham A, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute 's Surveillance, Epidemiology, and End Results database[J]. Cancer,2007,110(4):876-884.
|
| [11] |
Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer[J]. Breast Cancer Res Treat,2008,109(1):123-139.
|
| [12] |
Dolle JM, Daling JR, White E, et al. Risk actors for triple-negative breast cancer in women under the age of 45 years[J]. Cancer Epidemiol Biomarkers Prev,2009,18(4):1157-1166.
|
| [13] |
Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases[J].Cancer,2008,113(10):2638-2645.
|
| [14] |
王姝姝.三阴性乳腺癌患者远处复发转移的位置及临床结果:高发的脑转移率[J/CD].中华乳腺病杂志:电子版,2009,3(1):113-117.
|
| [15] |
Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J]. BMC Cancer,2007,7(24):134.
|
| [16] |
Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triplenegative breast cancer[J]. J Clin Oncol,2008,26(8):1275-1281.
|
| [17] |
Bidard FC, Matthieu MC, Chollet P, et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes[J]. Ann Oncol,2008,19(7):1261-1265.
|
| [18] |
Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase Ⅲtrials evaluating the predictive value of HER-2 and topoisomerase Ⅱalpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy[J].Cancer Res,2009,69(12):705.
|
| [19] |
O'Malley FP, Chia S, Tu D, et al. Topoisomerase Ⅱalpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial[J].Breast Cancer Res Treat,2011,128(2):401-409.
|
| [20] |
Jacquemier J, Penault-Llorca F, Mnif H, et al. Identification of a basal-like subtype and comparative effect of epirubicinbased chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA) [J]. J Clin Oncol,2006,24(3):509 .
|
| [21] |
Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342[J]. Breast Cancer Res,2006,8(6):66.
|
| [22] |
Ellis P, Barret-Lee P, Johnson L, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT):an open-label, phase Ⅲ, randomised controlled trial[J]. Lancet,2009,373(9676):1681-1692.
|
| [23] |
Silver DP, Richardson AL,Eklund AC,et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer[J]. J Clin Oncol,2010,28(7):1145-1153.
|
| [24] |
Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer[J]. Ann Oncol,2008,19(11):1847-1852.
|
| [25] |
Hoadley KA, Weigman VJ, Fan C, et al. EGFR associated expression profiles vary with breast tumor subtype[J]. BMC Genomics,2007,8(31):258.
|
| [26] |
Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer[J]. Ann Oncol,2009,20(5):862-867.
|
| [27] |
O'Shaughnessy J, Weckstein D, Vukelja S, et al. Preliminary results of a randomized phase Ⅱ study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer[J]. Breast Cancer Res Treat,2007,106(6):32.
|
| [28] |
Baselga J, Gomez P, Awada A, et al. The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): Results of a randomized phase Ⅱstudy (BALI-1)[J]. Ann Oncol,2010,21(4):2740.
|
| [29] |
Finn RS, Lau A, Kalous O, et al. Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents[J]. Cancer Res,2009,69(16):1038.
|
| [30] |
O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201,a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor,in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC):Results of a randomized phase Ⅱtrial[J]. J Clin Oncol,2009,27(18):793.
|